Literature DB >> 1851720

Expression of ABH blood group antigens, receptors of Ulex europaeus agglutinin I, and factor VIII-related antigen on sinusoidal endothelial cells in adenomatous hyperplasia in human cirrhotic livers.

T Terada1, Y Nakanuma.   

Abstract

Adenomatous hyperplasia, a hyperplastic parenchymal nodule in the cirrhotic liver, has been presumed to be a preneoplastic lesion in human hepatocarcinogenesis. In this study, phenotypes of the sinusoidal endothelium were examined in adenomatous hyperplasia, hepatocellular carcinoma, cirrhosis, chronic active hepatitis, and normal livers. Adenomatous hyperplasia (n = 74) was histologically classified into two types: ordinary (n = 35) and atypical (n = 39). While the former lacked hepatocellular atypia, the latter consisted of atypical hepatocytes equivocal as to benignity and malignancy, in some of which overt malignant foci were found. The expression of A, B, and H blood group antigens, receptors of Ulex europaeus agglutinin I, and factor VIII-related antigen on the sinusoidal endothelium was minimal or nil in normal livers. It was mild and focal in chronic active hepatitis, cirrhosis, and ordinary adenomatous hyperplasia, while expression was moderate in atypical adenomatous hyperplasia with or without malignant foci, and severe in malignant foci in atypical adenomatous hyperplasia and in hepatocellular carcinoma. These data suggest that phenotypes of the sinusoidal endothelium of atypical adenomatous hyperplasia are closely related to the development of hepatocellular carcinoma, and phenotypic changes of the sinusoidal endothelium occur stepwise corresponding to various stages of hepatocarcinogenesis in cirrhotic livers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851720     DOI: 10.1016/0046-8177(91)90136-d

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Noninvasive Intracystic Oncocytic Papillary Neoplasm of the Gall Bladder.

Authors:  Tadashi Terada
Journal:  J Gastrointest Cancer       Date:  2016-09

2.  Histopathological and morphometric analysis of atypical adenomatous hyperplasia of human cirrhotic livers.

Authors:  T Terada; K Ueda; Y Nakanuma
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

3.  Adenomatous hyperplasia of the liver resembling focal nodular hyperplasia in patients with chronic liver disease.

Authors:  T Terada; S Kitani; K Ueda; Y Nakanuma; K Kitagawa; S Masuda
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

4.  Unusual hepatocellular lesions in primary biliary cirrhosis resembling but unrelated to hepatocellular neoplasms.

Authors:  Y Nakanuma; K Hirata
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

5.  A case of small well-differentiated hepatocellular carcinoma with marked lymphocytic infiltrate.

Authors:  Tomohiro Iwasaki; Aki Kubota; Makoto Suzuki; Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

6.  Cutaneous pseudolymphoma: a case report with an immunohistochemical study.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

7.  ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B.

Authors:  Qiang Li; Cui-Hua Yu; Jin-Hong Yu; Li Liu; Shuang-Shuang Xie; Wen-Wen Li; Xia Yang; Wen-Bo Fan; Zhong-Tao Gai; Shi-Jun Chen; Naoya Kato
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

8.  ABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy.

Authors:  Tao Wu; Xiao-An Ma; Guo-Qing Wang; Qing Li; Miao-Jing Li; Jin-Yue Guo; Xuan Liang; Zhi-Ping Ruan; Tao Tian; Ke-Jun Nan; Li-Na Liu; Hui Guo
Journal:  Sci Rep       Date:  2017-06-30       Impact factor: 4.379

9.  Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.

Authors:  Qing Li; Tao Wu; Xiao-An Ma; Li Jing; Li-Li Han; Hui Guo
Journal:  Ther Clin Risk Manag       Date:  2018-05-29       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.